SciClone Reaches Agreement to Settle FCPA Derivative Suit
The suit — a consolidation of four similar plaintiff’s actions — alleged the Foster City, Calif.-based drugmaker made material misstatements about its financial results based on allegedly illegal and improper sales and marketing activities of hepatitis drug Zadaxin in China.
This story is exclusively for members of the
JUST ANTI-CORRUPTION COMMUNITY
Subscribe







